Back to Journals » International Journal of Nanomedicine » Volume 14

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Authors Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC

Received 1 March 2019

Accepted for publication 1 March 2019

Published 24 July 2019 Volume 2019:14 Pages 5751—5752

DOI https://doi.org/10.2147/IJN.S207276


Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209

On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication.
Read the original article

Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201–1209.

On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication and should read “Dr Burris reports a payment to his institution, Sarah Cannon Research Institute, from Yakult Honsha during the conduct of the study; grants to his institution for studies on which he served as Principal Investigator outside of the submitted work from the following companies: Acerta Pharma, Agios, Amgen, Amplimmune, Array BioPharma, AstraZeneca, BIND Therapeutics, BioMed Valley Discoveries, Inc., Celgene, eFFECTOR Therapeutics, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, Immunocore, Intellikine, Janssen, Loxo Oncology, MacroGenics, MedImmune, Medivation, Millennium Pharmaceuticals, Novartis, Pfizer, Sanofi, Seattle Genetics, Stem CentRx, Tesaro, TG Therapeutics, Verastem, and Vertex Pharmaceuticals. Dr Burris reports consulting fees paid to his institution for his services from the following companies: Bristol Myers Squibb, Nippon-Kayaku, Intellisphere, Novartis, Genentech, BIND Therapeutics, and AstraZeneca. Dr Burris reports non-financial support to his institution from AstraZeneca, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Millennium, Novartis, Sanofi, Amgen, Hoffman-LaRoche, Ventana, Grifols USA, and Astellas Pharmaceuticals. Dr Keedy reports clinical trial management costs from Yakult Honsha during the conduct of the study; grants outside the submitted work from Abraxis and personal fees outside the submitted work from Ziopharm. Dr Keedy also reports other financial sponsorship outside the submitted work to her institution, Vanderbilt University, from the following companies: Amgen, Ariad, Genentech, Janssen Pharmaceutical Companies of Johnson & Johnson, Merrimack, Nereus, Novartis, Pfizer, Threshold, U3 Pharma and Ziopharm. Dr Chan reports a payment to her institution, Vanderbilt University, from Yakult Honsha during the conduct of the study and outside the submitted work has served as an advisory board member for Amgen. Dr Bendell reports research funding to her institution, Sarah Cannon Research Institute, from Gilead, Genentech a member of the Roche group, Bristol-Myers Squibb, Five Prime, Eli Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GlaxoSmithKline, Novartis, OncoMed, Leap Therapeutics, TG Therapeutics, AstraZeneca, Boehringer Ingelheim (BI), Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Cytomx, Nektar, ARMO BioSciences Inc, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, Forma Therapeutics, Merus, Jacobio, Effecto, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Oncology, Unum Therapeutics, Vyriad, Harpoon, ADC Therapeutics, Amgen, Pfizer, Millennium, Imclone, Acerta Pharma, Rgenix, and Bellicum. Dr Bendell reports consulting/advisory fees paid to her institution for her services from the following companies: Gilead, Genentech a member of the Roche group, Bristol-Myers Squibb, Five Prime, Eli Lilly, Merck, MedImmune, Celgene, Taiho, Macrogenics, GlaxoSmithKline, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, ARMO BioSciences Inc, Ipsen, Merrimack, Oncogenex, FORMA, Arch Oncology, Prelude Therapeutics, Phoenix Bio, Cyteir, Molecular Partners, Innate, Torque, Tizona, Janssen, Tolero, TD2 (Translational Drug Development), Amgen, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Agois, and Kyn. Dr. Bendell also received food/beverage and travel allowances from Gilead, Genentech a member of Roche group, Bristol-Myers Squibb, Eli Lilly, Merck, MedImmune, Celgene, Taiho, Novartis, OncoMed, BI, ARMO BioSciences Inc, Ipsen, Oncogenes, and FORMA. Dr Rothenberg reports he received funding from Yakult Honsha and he is currently an employee of Pfizer. Dr Zamboni reports fundings from Yakult Pharmaceuticals to perform the pharmacokinetic studies and he works as a consultant for Yakult Honsha. The authors report no other conflicts of interest in this work”.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]